Array BioPharma to Present at the Jefferies 2019 Global Healthcare Conference

May 29, 2019 |

1 min read

Array BioPharma Inc. (Nasdaq: ARRY) today announced that its Chief Executive Officer, Ron Squarer, will speak at the Jefferies 2019 Global Healthcare Conference in New York City.

BOULDER, Colo., May 29, 2019 /PRNewswire/ -- Array BioPharma, Inc. (Nasdaq: ARRY) today announced that its Chief Executive Officer, Ron Squarer, will speak at the Jefferies 2019 Global Healthcare Conference in New York City. The public is welcome to participate in the conference through a webcast on the Array BioPharma website.

Event:	Jefferies 2019 Global Healthcare Conference
Presenter:	Ron Squarer, Chief Executive Officer, Array BioPharma
Date:	June 5, 2019
Time:	9:00 a.m. Eastern Time
Webcast:	http://wsw.com/webcast/jeff118/arry/

About Array BioPharma
Array BioPharma Inc. is a fully integrated biopharmaceutical company focused on the discovery, development and commercialization of transformative and well-tolerated targeted small molecule drugs to treat patients afflicted with cancer and other high-burden diseases. Array markets BRAFTOVI^® (encorafenib) capsules in combination with MEKTOVI^® (binimetinib) tablets for the treatment of patients with unresectable or metastatic melanoma with a BRAF^V600E or BRAF^V600Kmutation in the United States and with partners in other major worldwide markets. Array’s lead clinical programs, encorafenib and binimetinib, are being investigated in over 30 clinical trials across a number of solid tumor indications, including a Phase 3 trial in BRAF-mutant metastatic colorectal cancer. Array’s pipeline includes several additional programs being advanced by Array or current license-holders, including the following programs currently in registration trials: selumetinib (partnered with AstraZeneca), LOXO-292 (partnered with Eli Lilly), ipatasertib (partnered with Genentech), tucatinib (partnered with Seattle Genetics) and ARRY-797. Vitrakvi^® (larotrectinib, partnered with Bayer AG) is approved in the United States and Ganovo^® (danoprevir, partnered with Roche) is approved in China. For more information on Array, please visit www.arraybiopharma.com or follow @arraybiopharma on Twitter and LinkedIn.